



Digestive Diseases Research Seminar
*Presented by Yale School of Medicine,
Department of Internal Medicine, and Section of Digestive Diseases*

YaleCME
CONTINUING MEDICAL EDUCATION

Gastrointestinal and hepatotoxicity from immune checkpoint inhibitors

Ashley Tran, MD

Fellow of Medicine

Department of Medicine (Digestive Diseases)

Yale School of Medicine

Tuesday, May 18, 2021

5:00 - 6:00 pm

<https://zoom.us/j/92129994229?pwd=L0FlRlRlY2Yi9KZmp5TnNhS3hGaTVlUT09>

Hosts: Badr Al Bawardy, MD and David N. Assis, MD

To record your attendance to this activity, text the Activity Code (20557) for your RSS activity to 203-442-9435.
You will receive a message back that verifies your activity attendance has been recorded for CME credit.

There is no corporate support for this activity. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **Target Audience:** YSM faculty, fellows, nurses, residents, medical students, staff, and other health care providers. **Designation Statement:** The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity. **Needs assessment:** Immune checkpoint inhibitors (ICIs) have transformed the treatment for advanced malignancies by improving long-term clinical response and leading to durable remission in a subset of patients. These agents can also cause a broad range of potentially life-threatening inflammatory toxicities, many of which involve the gastrointestinal tract (GI) and liver. Therefore, it is important for gastroenterologists and hepatologists to be aware of these events and provide expertise on the diagnosis and management of ICI-related gastrointestinal and hepatotoxicity. **Objectives:** To review the clinical presentation and management of ICI-related gastrointestinal and hepatotoxicity; To identify the risk factors for the development of ICI-related gastrointestinal and hepatotoxicity; To discuss the safety of resuming ICIs after clinically significant ICI-related gastrointestinal and hepatotoxicity. **Faculty Disclosures:** A Tran – None; D Assis – None; B Al Bawardy – Abbvie, Takeda, Bristol-Meyers Squibb. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. **This course will fulfill the licensure requirement set forth by the State of Connecticut.**